Advice

in the absence of a submission from the holder of the marketing authorisation:

brentuximab vedotin (Adcetris®) is not recommended for use within NHSScotland.

Indication under review: treatment of adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with doxorubicin, vinblastine and dacarbazine.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.

Download detailed advice356KB (PDF)

Download

Medicine details

Medicine name:
brentuximab vedotin (Adcetris)
SMC ID:
SMC2202
Indication:
Treatment of adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with doxorubicin, vinblastine and dacarbazine.
Pharmaceutical company
Takeda UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published:
10 June 2019